This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Freifeld, A.
Right arrow Articles by Wheat, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freifeld, A.
Right arrow Articles by Wheat, L. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2009, p. 1648-1651, Vol. 53, No. 4
0066-4804/09/$08.00+0     doi:10.1128/AAC.01148-07
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Voriconazole Use for Endemic Fungal Infections{triangledown}

Alison Freifeld,1* Laurie Proia,2 David Andes,3 Larry M. Baddour,4 Janis Blair,5 Brad Spellberg,6 Sandra Arnold,7 Arnold Lentnek,8 and L. Joseph Wheat9

University of Nebraska Medical Center, Omaha, Nebraska,1 Rush Medical College, Chicago, Illinois,2 University of Wisconsin, Madison, Wisconsin,3 Mayo Clinic, Rochester, Minnesota,4 Mayo Clinic, Phoenix, Arizona,5 Harbor—UCLA, Los Angeles, California,6 University of Tennessee, Memphis, Tennessee,7 Wellstar Clinical Trials, Marietta, Georgia,8 Miravista Labs, Indianapolis, Indiana9

Received 30 August 2007/ Returned for modification 31 October 2007/ Accepted 4 January 2009

In a retrospective review of 24 patients with histoplasmosis, blastomycosis, or coccidioidomycosis treated with voriconazole (most for salvage therapy), the outcome was favorable (improved or stable) for 22 (95.8%) within 2 months of starting voriconazole and for 20 (83.3%) at the last follow-up. Prospective studies are required to determine its role in the treatment of endemic mycoses.

* Corresponding author. Mailing address: 985400 Nebraska Medical Center, Omaha, NE 68198. Phone: (402) 559-8650. Fax: (402) 559-5581. E-mail: afreifeld{at}unmc.edu

{triangledown} Published ahead of print on 12 January 2009.

Antimicrobial Agents and Chemotherapy, April 2009, p. 1648-1651, Vol. 53, No. 4
0066-4804/09/$08.00+0     doi:10.1128/AAC.01148-07
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ta, M., Flowers, S. A, Rogers, P D. (2009). The Role of Voriconazole in the Treatment of Central Nervous System Blastomycosis. The Annals of Pharmacotherapy 43: 1696-1700 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»